Solid Tumor Cancer Treatment Market Report 2026

Solid Tumor Cancer Treatment Market Overview

• Solid Tumor Cancer Treatment market size has reached to $265.41 billion in 2025 • Expected to grow to $501.28 billion in 2030 at a compound annual growth rate (CAGR) of 13.6% • Growth Driver: Escalating Cancer Incidence Fuels Advancements In Solid Tumor Cancer Treatment Market • Market Trend: Advancements In Innovative Cancer Therapies • North America was the largest region in 2025.

What Is Covered Under Solid Tumor Cancer Treatment Market?

Solid tumor cancer treatment refers to the treatment of an aberrant mass of tissue that does not generally contain cysts or liquid regions. The majority of the tumor's cells are created by cancer stem cells through division. The objective of solid tumor cancer treatment is to enhance patient outcomes by managing disease progression, reducing symptoms, improving quality of life, and boosting survival rates. The main types of treatment for solid tumor cancer are chemotherapy, targeted therapy, immunotherapy, hormone therapy, and surgical procedures. Chemotherapy refers to a therapy that uses drugs to stop the division or kill cancer cells to stop their proliferation. They are used for several applications, including breast cancer, cervical cancer, colorectal cancer, lung cancer, prostate cancer, and others, and are used by various end-users, such as hospitals, research institutes, and home care.

What Is The Solid Tumor Cancer Treatment Market Growth Forecast?

The solid tumor cancer treatment market size is expected to see rapid growth in the next few years. It will grow to $501.28 billion in 2030 at a compound annual growth rate (CAGR) of 13.6%. The growth in the forecast period can be attributed to immunotherapy approvals, targeted drug pipelines, personalized medicine adoption, oncology infrastructure expansion, survival rate improvements. Major trends in the forecast period include growth of checkpoint inhibitors, expansion of tumor-agnostic therapies, increased use of combination regimens, rising biomarker-driven treatment, outpatient oncology growth.

Global Solid Tumor Cancer Treatment Market Segmentation

1) By Type: Chemotherapy, Targeted Therapy, Immunotherapy, Hormone Therapy, Surgical Procedures 2) By Application: Breast Cancer, Cervical Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Other Applications 3) By End-Users: Hospitals, Research Institutes, Homecare Subsegments: 1) By Chemotherapy: Alkylating Agents, Antimetabolites, Anthracyclines, Mitotic Inhibitors 2) By Targeted Therapy: Monoclonal Antibodies, Small Molecule Inhibitors, Signal Transduction Inhibitors 3) By Immunotherapy: Checkpoint Inhibitors, CAR T-Cell Therapy, Cancer Vaccines 4) By Hormone Therapy: Aromatase Inhibitors, Anti-Androgens, Selective Estrogen Receptor Modulators (SERMs) 5) By Surgical Procedures: Tumor Resection, Laparoscopic Surgery, Robotic-Assisted Surgery

What Is The Driver Of The Solid Tumor Cancer Treatment Market?

The increasing incidence of cancer significantly contributes to the growth of the solid tumor cancer treatment market going forward. Cancer is a severe disorder in which the body's cells reproduce fast and uncontrollably, resulting in abnormal growth. Solid tumor cancer treatment refers to a treatment that is used to remove the solid tumor from the body of patients who have cancer. For instance, in April 2024, according to the World Health Organization, a Switzerland-based international public health organization, in 2022, nearly 20 million new cancer cases were reported, resulting in approximately 10 million deaths due to the disease. Demographic projections suggest that the annual incidence of cancer could rise to 35 million by 2050, marking a 77% increase from 2022 figures. Lung cancer was the most commonly diagnosed type, accounting for about 2.5 million new cases, or one in every eight cancers globally, representing 12.4% of all cancers worldwide. Therefore, an increasing incidence of cancer is driving the growth of the solid tumor cancer treatment industry.

Key Players In The Global Solid Tumor Cancer Treatment Market

Major companies operating in the solid tumor cancer treatment market are AstraZeneca plc, Amgen Inc., Bristol Myers Squibb & Company, Eli Lilly & Company, F Hoffmann La Roche Ltd, Merck & Co Inc, Novartis AG, Pfizer Inc, Olympus Medical Systems, Astellas Pharma Inc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Ltd, Celldex Therapeutics Inc, AbbVie Inc, Bayer AG, Eisai Co Ltd, Exelixis Inc, Genentech Inc, Gilead Sciences Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Karyopharm Therapeutics Inc, Kyowa Kirin Co Ltd, MorphoSys AG, Regeneron Pharmaceuticals Inc, Sanofi SA, Seattle Genetics Inc, Spectrum Pharmaceuticals Inc, Taiho Pharmaceutical Co Ltd, Verastem Inc, Zymeworks Inc

Global Solid Tumor Cancer Treatment Market Trends and Insights

Major companies operating in the solid tumor cancer treatment market are focusing on developing advanced immunotherapies, targeted therapies, and cell-based treatments to improve patient outcomes and expand therapeutic options. For instance, in July 2025, Dispatch Bio, a US-based biotechnology company, launched operations to develop universal treatments for solid tumors. The company aims to advance novel therapeutic approaches that target a broad range of solid tumor types, enhance efficacy across patient populations, and accelerate the development of scalable cancer immunotherapies, potentially transforming standard-of-care treatment and improving long-term survival rates.

What Are Latest Mergers And Acquisitions In The Solid Tumor Cancer Treatment Market?

In February 2024, AbbVie Inc., a US-based pharmaceutical company acquired ImmunoGen, Inc. With this acquisition, AbbVie aims to strengthen its oncology capabilities by specifically addressing unmet needs in cancer treatments. The company seeks to enhance its solid tumor portfolio and expand its presence in the oncology market. ImmunoGen, Inc. is a U.S.-based biotechnology company that develops antibody-drug conjugate (ADC) therapeutics for the treatment of cancer.

Regional Outlook

North America was the largest region in the solid tumor cancer treatment market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Solid Tumor Cancer Treatment Market?

The solid tumor cancer treatment market includes revenues earned by entities by treat solid tumor cancer through hormonal therapy, targeted drugs, and immunotherapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Solid Tumor Cancer Treatment Market Report 2026?

The solid tumor cancer treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the solid tumor cancer treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.